<DOC>
	<DOCNO>NCT02052388</DOCNO>
	<brief_summary>The purpose study determine safety efficacy three different dose regimen brilacidin compare daptomycin treatment serious skin infection . This study aid select appropriate dose brilacidin later stage study .</brief_summary>
	<brief_title>Efficacy Safety Study Brilacidin Treat Serious Skin Infections</brief_title>
	<detailed_description>This randomize , multi-center , double-blind study evaluate efficacy safety three regimen brilacidin compare active control , daptomycin , subject ABSSSI . Subjects must infections warrant intravenous therapy may treat either inpatient outpatient . Eligible subject randomize one 4 treatment group 1:1:1:1 ratio . Subjects randomize brilacidin receive either single intravenous infusion ( 0.6 mg/kg 0.8 mg/kg ) follow six day daily placebo , three day regimen ( 0.6 mg/kg Day 1 follow 0.3 mg/kg Days 2 3 ) follow 4 day daily placebo . Subjects randomize daptomycin receive 7 day treatment . Subjects assess clinical microbiologic efficacy 48-72 hour first dose study drug . After assessment Day 7-8 , subject evaluated efficacy Day 10-14 via phone contact Day 21-28 . Approximately 200 subject randomize 1:1:1:1 ratio receive one three brilacidin regimens daptomycin evaluable . The primary efficacy outcome , early clinical response 48-72 hour first dose study drug , determine Intent-to treat ( ITT ) population . Additional efficacy safety analyse perform .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<criteria>Provision write informed consent Be ≥ 18 ≤ 85 year age Have one follow type ABSSSI : 1 . A posttraumatic postsurgical wound infection , occur within 30 day trauma surgery , characterize purulent seropurulent drainage wind surround erythema , edema and/or induration minimum surface area 75 cm2 . 2 . A major cutaneous abscess , characterize collection pu within dermis deep tissue , accompany erythema , edema , and/or induration minimum surface area 75 cm2 . Note : patient major cutaneous abscess limit 30 % total enrollment 3 . Cellulitis/erysipelas , characterize spread area erythema , edema , and/or induration minimum surface area 75 cm2 . Have two follow sign : 1 . Purulent seropurulent drainage discharge 2 . Erythema 3 . Fluctuance 4 . Heat localize warmth 5 . Pain tenderness palpation Have one follow systemic sign : 1 . Temperature ( oral tympanic ) ≥ 38⁰ C/100.4 F , measure subject/caregiver investigator 24 hour prior baseline 2 . WBC count &gt; 10,000/mm3 3 . Greater 10 % band immature neutrophil ( total ) , irrespective WBC count 4 . Elevated Creactive protein ( CRP ) ( &gt; 40 mg/L ) , test 5 . Presence lymphadenitis lymphadenopathy proximal infected area Must receive single dose shortacting systemic antibiotic current ABSSSI within 72 hour prior randomization , unless either following situation apply : 1 . Clinical evidence treatment failure follow least 48 hour prior systemic antimicrobial therapy ; 2 . The subject recently complete course antibiotic treatment infection ABSSSI drug active bacterial pathogen typically cause ABSSSI . Female subject pregnant , lactate ( breast milk feeding ) , plan pregnancy course study . Skin skin structure infection follow characteristic : 1 . Presence uncomplicated skin skin structure infection , folliculitis , furunculosis , minor abscess likely respond incision drainage alone 2 . Suspected confirm osteomyelitis 3 . Suspected confirm septic arthritis 4 . Suspected confirmed infection cause exclusively Gramnegative pathogen anaerobes Known hypersensitivity daptomycin Known creatinine clearance &lt; 50 mL/min ( base CockcroftGault formula use ideal body weight ) Immunosuppression , define chronic corticosteroid use ( 20 mg prednisone/day equivalent ) , solid organ bone marrow transplantation , current cytotoxic chemotherapy , neutropenia ( absolute neutrophil count &lt; 500/mm3 ) , know HIV infection CD4+ count &lt; 200/mm3 Platelet count &lt; 50 x 103/L Exhibits sign sepsis : 1 . Shock profound hypotension , define systolic blood pressure &lt; 90 mm Hg decrease &gt; 40 mm Hg baseline responsive fluid challenge ; 2 . Hypothermia ( core temperature &lt; 35.6°C &lt; 96.1°F ) ; 3 . Disseminated intravascular coagulation evidence prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) 2 time upper limit normal ; Inability unwillingness adhere studyspecified procedure restriction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Skin Infection</keyword>
	<keyword>Staph aureus</keyword>
	<keyword>MRSA</keyword>
	<keyword>MSSA</keyword>
	<keyword>Cellulitis/Erysipelas</keyword>
	<keyword>Wound Infection</keyword>
	<keyword>Abscess</keyword>
</DOC>